| 000 | 01100 a2200313 4500 | ||
|---|---|---|---|
| 005 | 20250515201045.0 | ||
| 264 | 0 | _c20100304 | |
| 008 | 201003s 0 0 eng d | ||
| 022 | _a1474-547X | ||
| 024 | 7 |
_a10.1016/S0140-6736(09)62103-6 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPhillips, Andrew | |
| 245 | 0 | 0 |
_aDART points the way for HIV treatment programmes. _h[electronic resource] |
| 260 |
_bLancet (London, England) _cJan 2010 |
||
| 300 |
_a96-8 p. _bdigital |
||
| 500 | _aPublication Type: Comment; Journal Article | ||
| 650 | 0 | 4 |
_aAnti-Retroviral Agents _xtherapeutic use |
| 650 | 0 | 4 | _aCD4 Lymphocyte Count |
| 650 | 0 | 4 | _aDrug Monitoring |
| 650 | 0 | 4 | _aDrug Resistance, Viral |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 |
_aHIV Infections _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aRandomized Controlled Trials as Topic |
| 650 | 0 | 4 | _aViral Load |
| 700 | 1 | _avan Oosterhout, Joep | |
| 773 | 0 |
_tLancet (London, England) _gvol. 375 _gno. 9709 _gp. 96-8 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/S0140-6736(09)62103-6 _zAvailable from publisher's website |
| 999 |
_c19386553 _d19386553 |
||